Dallara Que 4

What Happened
Dallara Que, CEO of MiniMed Group, received two derivative equity awards on March 9, 2026: 83,334 and 252,526 units (total 335,860). Both were reported as awards/grants (transaction code A) with an acquisition price of $0.00 because they are restricted stock units/options that only convert to shares if/when they vest and any vesting conditions are satisfied. No open‑market purchases, sales, or cash exercises were reported.

Key Details

• Transaction date: 2026-03-09; Form 4 filed 2026-03-11 (appears timely).
• Awards: 83,334 and 252,526 units; grant price $0.00 (derivative awards/RSUs). Total units granted = 335,860.
• Post-transaction holdings: Not specified in the filing.
• Notable footnotes from the filing:
  • F1: One set of units are performance-based RSUs (each converts to one share) and vest on March 9, 2027 only if MMED common stock achieves a closing price of at least $32.05 as of the referenced “Divestment Date.”
  • F2: Vesting is tied to the later of March 9, 2027 or the Divestment Date (per the Separation Agreement cited).
  • F3: Another award follows a multi‑year vesting schedule (33% vest March 9, 2028; 33% March 9, 2029; 34% March 9, 2030).
• Transaction type: A = Award/Grant (derivative/RSU style); no immediate cash value and shares only issued on vesting.

Context
These grants are compensation awards that are contingent on time- and/or performance-based vesting conditions; they do not represent an immediate cash purchase or sale. For retail investors, such awards signal company compensation decisions but are not the same as an insider buying shares on the open market. The awards will only translate into actual shares (and potential economic benefit) if the specified vesting and performance conditions are met.